MarginsXMarginsX
Home › Markets › Health Care › PLYX

Polaryx Therapeutics Inc. (PLYX)

PLYX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.67
-6.99% on the day
Market cap
$83.2M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPLYX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002075320
SEC industry codePharmaceutical Preparations
Incorporated inWY

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
12.6 months
$8.4M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$368K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued."
10-Q 2026-11-12
Cash and burn$8.4M cash; operating cash flow -$2.0M a quarter.Report 2026-09-30
Shares outstanding49,845,993 (2026-10-31).Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Edison, New Jersey, United StatesPCAOB Form AP 2026-03-25
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $368K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$3.3M-$3.1M$8.4MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$1.4M-$1.4M$11.5MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$2.5M-$2.1M$3.1MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q4 2025
2025-12-31
Not filed-$1.5M-$1.5M$5.1MNo debt tagsNeeds four quarters10-K 2026-03-24
Q3 2025
2025-09-30
Not filed-$1.4M-$887KNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$1.0M-$858KNot filedNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2025
2025-03-31
Not filed-$5.1M-$709KNot filedNo debt tagsNeeds four quarters10-Q 2026-05-15

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42026-02-02
Latest annual report
ANNUAL REPORT
10-K2026-03-24
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-09-14
Latest proxy
DEFINITIVE ADDITIONAL MATERIALS
DEFA14A2026-07-28

Source: SEC EDGAR submissions feed, 36 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.7%
1 month-8.8%
3 months-29.2%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-94.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RLYBRallybio Corporation$15.43-1.88%$86.4M
NKTXNkarta Inc.$1.21+1.68%$86.8M
GNLXGenelux Corporation$1.92+2.95%$86.9M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
CPIXCumberland Pharmaceuticals Inc.$5.21-11.39%$78.1M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier